Publication | Closed Access

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Lymphoid NeoplasiaRadioimmunotherapy Dosimetry ResultsPhase I/ii 90MedicineYttrium-90 Ibritumomab TiuxetanPathologyLymphatic DiseaseImmunotherapyOncologyRadiation Oncology